Biotech | December 15, 2021
Aragen Life Sciences acquires Intox
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorised in the US to prevent Covid-19
This further adds to Biocon’s portfolio of vertically integrated complex drug products
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
The division is expected to grow to over a 100-member strong team by 2022
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
Subscribe To Our Newsletter & Stay Updated
